Key Dates and Events
- 37th AGM Date: Tuesday, August 4, 2026 at 12:30 p.m.
- AGM Format: Video Conference/Other Audio-Visual Means (VC/OAVM)
- Record Date: Tuesday, July 28, 2026 for dividend entitlement and voting
- Remote e-Voting Period: July 31, 2026 (9:00 a.m.) to August 3, 2026 (5:00 p.m.)
- Dividend Payment Date: On or before August 28, 2026 (if approved)
- Financial Year: April 1, 2025 to March 31, 2026
Financial Performance Highlights (₹ in Lakhs)
| Particulars | 2025-26 | 2024-25 | Change |
| Total Income | 9,188.93 | 7,878.69 | +16.63% |
| Profit Before Tax | 1,407.35 | 887.82 | +58.52% |
| Profit After Tax | 1,039.58 | 656.62 | +58.32% |
| Share Capital | 1,154.40 | 1,154.40 | No change |
| Reserves & Surplus | 6,169.37 | 5,247.77 | +17.56% |
| Net Worth | 7,323.77 | 6,402.17 | +14.40% |
| Earnings Per Share (₹) | 9.01 | 5.69 | +58.35% |
| Book Value Per Share (₹) | 63.44 | 55.46 | +14.39% |
Dividend Declaration
- Recommended equity dividend of ₹1 per share (10%)
- Dividend amount: ₹115.44 lakhs
- Payable on or before August 28, 2026 if approved at AGM
AGM Agenda Items
Ordinary Business
1. Adoption of audited financial statements for FY 2025-26
2. Re-appointment of Mr. Charchit Jain (DIN: 09344495) who retires by rotation
3. Declaration of dividend on equity shares
4. Re-appointment of M/s. Kailash Chand Jain & Co. as Statutory Auditors for second term of 5 years (Firm Registration No. 112318W)
Special Business
5. Approval for entering into Related Party Transactions with Kaygee Laboratories Private Limited up to maximum aggregate value of ₹40 crores in any financial year
6. Ratification of remuneration of Cost Auditor M/s. Poddar & Co. for FY 2026-27 at ₹1,75,000 plus applicable taxes and expenses
Key Financial Ratios
| Ratio | 2025-26 | 2024-25 |
| Debtors Turnover Ratio | 4.98 | 4.36 |
| Inventory Turnover Ratio | 2.10 | 2.23 |
| Interest Coverage Ratio | 67.41 | 30.96 |
| Current Ratio | 4.12 | 6.79 |
| Debt Equity Ratio | 0.032 | 0.055 |
| Operating Profit Margin (%) | 15.86% | 12.87% |
| Net Profit Margin (%) | 11.49% | 8.39% |
| Return on Net Worth (%) | 19.48% | 13.12% |
Related Party Transactions
- Related Party: Kaygee Laboratories Private Limited
- Nature of Relationship: Same promoter group, common directors (Mr. Prashant Godha and Mr. Charchit Jain)
- Transaction Value FY 2025-26: ₹17.36 crores
- Proposed Limit FY 2026-27: ₹40.00 crores annually
- Transaction Types: Purchase/sale of materials, contract manufacturing services, advances, lease and license arrangements
- Percentage of FY 2025-26 Income: 43.53%
- Basis: Arm's length, ordinary course of business
Credit Rating
- Agency: CRISIL Ratings
- Facility: Total bank loan facilities of ₹14 crores
- Rating: CRISIL BBB-/Stable (Long term)
Board of Directors
| Name | Designation | DIN |
| Mr. Ajay Patadia | Independent Director | 00298226 |
| Mrs. Dhara Shah | Independent Director | 07530998 |
| Mr. Prashant Godha | Non-Executive Director | 00012759 |
| Mr. Nilesh Jain | Non-Executive Director | 05263110 |
| Mr. Charchit Jain | Whole-time Director & CFO | 09344495 |
| Mr. Raj Kamal Prasad Verma | Chairman (Independent Director) | 02166789 |
Key Managerial Personnel
- Mr. Charchit Jain (Whole-time Director & CFO)
- Ms. Vaibhavi Shah (Company Secretary, ACS 72229)
Audit Reports
- Statutory Audit: Unmodified opinion with emphasis on inventory valuation and contingent liabilities as key audit matters
- Secretarial Audit: No qualifications, reservations or adverse remarks
- Cost Audit: Report for FY 2024-25 filed on August 11, 2025 within due date
Capital Structure
- Authorized Capital: ₹1,500.00 lakhs (1,50,00,000 equity shares of ₹10 each)
- Paid-up Capital: ₹1,154.40 lakhs (1,15,44,000 equity shares of ₹10 each)
- Dematerialization: 96.48% of paid-up capital as of March 31, 2026
Shareholding Pattern (as on March 31, 2026)
| Category | Shares (Lakhs) | Percentage |
| Indian Promoters | 62.62 | 54.25% |
| Resident Individual | 40.74 | 35.29% |
| Non-Resident Indians | 1.77 | 1.53% |
| Corporate Bodies | 2.06 | 1.78% |
| IEPF | 6.38 | 5.53% |
| Others | 1.87 | 1.62% |
| Total | 115.44 | 100.00% |
Major Shareholders (>5%)
- Makers Laboratories Ltd: 52.50 lakh shares (45.48%)
- Kaygee Investments Private Limited: 10.12 lakh shares (8.77%)
Borrowings and Debt
- Term Loan (Yes Bank): ₹206.01 lakhs (secured by movable fixed assets and current assets)
- Working Capital Facilities: ₹8 crores (secured by first charge on current assets)
- Current Maturities: ₹103.11 lakhs classified as current liabilities
- Interest Rate: 7.5%-8.5% linked to repo rate
Contingent Liabilities (₹ in Lakhs)
| Particulars | Amount |
| Bank Guarantees | 10.00 |
| MPCB and MSEDCL Guarantees | 53.10 |
| Maharashtra Pollution Control Board demands | 121.64 |
| Income Tax demand (AY 2017-18) | 17.64 |
| Total | 202.38 |
Commitments
- Letter of Credit Outstanding: ₹501.51 lakhs
- Capital Commitments: Not quantified in disclosure
CSR Activities
- CSR Expenditure FY 2025-26: ₹13.00 lakhs
- Recipient: Anvi Medical & Educational Foundation (CSR Registration No. CSR00012251)
- Activity: Medical healthcare projects in Vangani, Maharashtra
- CSR Committee Chairman: Mr. Raj Kamal Prasad Verma
Research & Development
- R&D Expenditure FY 2025-26: ₹21.08 lakhs (0.23% of turnover)
- R&D Focus: Catalysis for fluidized bed and fixed bed catalytic reactions, process optimization
- R&D Center: Tarapur, recognized by Department of Scientific and Industrial Research
Employee Benefits
- Gratuity Liability: ₹68.84 lakhs (funded status: ₹2.75 lakhs net liability)
- Leave Encashment Liability: ₹15.20 lakhs
- Total Employees: 74 permanent employees as of March 31, 2026
- Median Remuneration: ₹3,96,450
Important Notes
- The AGM will be conducted entirely through video conferencing without physical attendance
- Dividend warrants remaining unencashed for seven years transferred to IEPF
- Shares can only be transferred in dematerialized form as per Regulation 40 of SEBI Listing Regulations
- Email communication adopted for all shareholder communications